ReviewJACC. Advances2026
Heart Failure With Mildly Reduced Ejection Fraction: A Call for a Precision Medicine Approach.
Review in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Heart Failure with Reduced and Mildly Reduced Ejection Fraction: A Network Interpretive Framework of Mechanisms, Phenotypes, and Therapeutic Response.International journal of molecular sciences · 2026Review
- Amino Acid-Derived Metabolic Signature Across Stages of Systolic Dysfunction: Derivation and Internal Evaluation of the HASI (Heart Failure Amino Acid-Derived Systolic Index)-40 Index.International journal of molecular sciences · 2026Article
- The influence of C-reactive protein-triglyceride-glucose index (CTI) on the prognosis of heart failure patients with different ejection fractions.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with mildly reduced ejection fraction (HFmrEF) is increasingly recognized as a distinct yet heterogeneous phenotype within the heart failure spectrum. Advances in diagnostic tools, including strain imaging, cardiac magnetic resonance, and molecular imaging, together with progress in genomics and biomarker profiling, have contributed to a deeper understanding of the complex pathophysiology of HFmrEF. Although direct, high-quality clinical evidence remains limited due to inconsistent definitions and under-representation in major trials, recent studies and subgroup analyses have offered promising therapeutic options for HFmrEF patients. Given the significant heterogeneity of HFmrEF, future management strategies should focus on precision medicine and individualized care. Integrating advanced imaging, biomarker profiling, genomics, and phenotype-specific assessment will be essential for optimizing patient outcomes. Embracing this precision-based approach promises to redefine care pathways and improve prognosis for this under-recognized patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.